Case File Banner 24

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Show Description +

Joseph M. Coney, MD, presents the case of a patient with bilateral DME whose disease has been present for over a decade and is responsive to anti-VEGF treatment—but who is unable to extend beyond monthly treatment. After 52 injections of aflibercept 2 mg (Eylea, Regeneron) over the course of his disease, the patient responds well to faricimab (Vabysmo, Genentech/Roche) therapy and a slightly extended interval. What approaches would Priya Sharma Vakharia, MD, and Yasha S. Modi, MD, take moving forward with this patient?

Posted: 1/15/2024

Up Next


Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Joseph M. Coney, MD, presents the case of a patient with bilateral DME whose disease has been present for over a decade and is responsive to anti-VEGF treatment—but who is unable to extend beyond monthly treatment. After 52 injections of aflibercept 2 mg (Eylea, Regeneron) over the course of his disease, the patient responds well to faricimab (Vabysmo, Genentech/Roche) therapy and a slightly extended interval. What approaches would Priya Sharma Vakharia, MD, and Yasha S. Modi, MD, take moving forward with this patient?

Posted: 1/15/2024


Please log in to leave a comment.